S
Syros Pharmaceuticals
Biotech & Life Sciences · Watertown, United States · Founded 2012 · IPO 2016
Redefining the power of small molecules to control gene expression and to provide a profound benefit for patients MoreLess
Syros Pharmaceuticals is a biopharmaceutical company focused on developing innovative gene control medicines to treat cancer and genetic diseases. The company operates in the healthcare and biotechnology market, primarily serving patients with acute myeloid leukemia and select solid tumors. Syros' business model revolves around the research, development, and commercialization of small molecule therapies that precisely control gene expression. The company generates revenue through partnerships, licensing agreements, and potential future sales of its proprietary medicines. Syros is advancing a pipeline that includes two investigational medicines in clinical trials and multiple programs in preclinical development. The company's approach leverages its expertise in gene control to create targeted therapies that aim to transform patient outcomes.
Keywords: gene control, small molecules, cancer therapy, genetic diseases, biopharmaceutical, acute myeloid leukemia, solid tumors, clinical trials, biotechnology, innovative medicines.
Talent graph
Syros Pharmaceuticals's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Syros Pharmaceuticals has talent and traffic
Market sentiment
What the market is saying about Syros Pharmaceuticals
An AI-synthesized read of the highest-engagement posts about Syros Pharmaceuticals on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Syros Pharmaceuticals on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

















